Evidence map›Paper›PMID 33855951›Full record

ReviewThe Journal of general virology2021

SARS-CoV-2 one year on: evidence for ongoing viral adaptation.

Thomas P Peacock, Rebekah Penrice-Randal, Julian A Hiscox, Wendy S Barclay

Open access · hybridAbstract readReview
In one paragraph

Review in The Journal of general virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 182 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. On the SARS-CoV-2 Variants.Infectious disease reports · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Thomas P PeacockDepartment of Infectious Diseases, St Marys Medical School, Imperial College London, UK.
Rebekah Penrice-RandalInstitute of Infection, Veterinary and Ecology Sciences, University of Liverpool, UK.
Julian A HiscoxInstitute of Infection, Veterinary and Ecology Sciences, University of Liverpool, UK.
Wendy S BarclayDepartment of Infectious Diseases, St Marys Medical School, Imperial College London, UK.
St Mary's Hospital · GBAgency for Science, Technology and Research · SGUniversity of Liverpool · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K002465/1Wellcome Trust 205100
6 · The paper itself

Abstract

SARS-CoV-2 is thought to have originated in the human population from a zoonotic spillover event. Infection in humans results in a variety of outcomes ranging from asymptomatic cases to the disease COVID-19, which can have significant morbidity and mortality, with over two million confirmed deaths worldwide as of January 2021. Over a year into the pandemic, sequencing analysis has shown that variants of SARS-CoV-2 are being selected as the virus continues to circulate widely within the human population. The predominant drivers of genetic variation within SARS-CoV-2 are single nucleotide polymorphisms (SNPs) caused by polymerase error, potential host factor driven RNA modification, and insertion/deletions (indels) resulting from the discontinuous nature of viral RNA synthesis. While many mutations represent neutral 'genetic drift' or have quickly died out, a subset may be affecting viral traits such as transmissibility, pathogenicity, host range, and antigenicity of the virus. In this review, we summarise the current extent of genetic change in SARS-CoV-2, particularly recently emerging variants of concern, and consider the phenotypic consequences of this viral evolution that may impact the future trajectory of the pandemic.

Indexed as

Adaptation, PhysiologicalAnimalsAntigens, ViralCOVID-19HumansImmune EvasionMutationRNA, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusViral ProteinsVirus InternalizationVirus ReplicationZoonosesAntigens, ViralRNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral ProteinsadaptationcoronavirusCOVID-19mutantpandemicSARS-CoV-2

Identifiers

PMID33855951
PMCPMC8290271
OpenAlexW3155593199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.